TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed price. Currency in USD
20.71
-0.77 (-3.58%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close21.48
Open21.05
Bid0.00 x 0
Ask0.00 x 0
Day's range20.27 - 21.14
52-week range10.85 - 37.94
Volume27,964,019
Avg. volume26,731,969
Market cap21.041B
Beta0.68
PE ratio (TTM)N/A
EPS (TTM)-5.87
Earnings dateN/A
Forward dividend & yield0.00 (0.00%)
Ex-dividend date2017-11-27
1y target est19.35
Trade prices are not sourced from all markets
  • How Hospitals Plan To Put Pressure On Generic-Drug Makers
    Investor's Business Daily8 hours ago

    How Hospitals Plan To Put Pressure On Generic-Drug Makers

    Generic-drug makers were hit Thursday after hospitals said they would make medicines themselves to circumvent high prices.

  • Globe Newswireyesterday

    Helsinn: US Court of Appeals for Federal Circuit Rejects Petition by Helsinn for Rehearing En Banc of Federal Circuit Panel Ruling That Certain Patents Covering Aloxi® in the US Market Are Invalid

    In the patent infringement lawsuit for antiemetic agent ALOXI® (palonosetron hydrochloride) injection brought by Helsinn Healthcare S.A. against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. (collectively "Teva"), the United States Court of Appeals for the Federal Circuit yesterday denied a petition by Helsinn for a rehearing en banc to review the panel decision issued on May 1st, 2017 by the Federal Circuit holding that certain patent claims covering Aloxi® (palonosetron hydrochloride) injection are not valid and therefore not infringed by Teva's generic palonosetron product. Helsinn will file for a stay of the mandate at the Federal Circuit and, if necessary, at the Supreme Court.

  • Teva Pharmaceutical: Still Focused on New Product Launches
    Market Realist2 days ago

    Teva Pharmaceutical: Still Focused on New Product Launches

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? The Vanguard Total International Stock ETF (VXUS) holds 0.09% of its total portfolio in TEVA stock. Teva Pharmaceutical Industries (TEVA) has its biggest value chain in the market as the company’s core strength, which has helped it establish itself as the leading generics pharmaceutical company in the world.

  • How This Biotech Stock Could Top Bigger Rivals In Preventing Migraines
    Investor's Business Daily2 days ago

    How This Biotech Stock Could Top Bigger Rivals In Preventing Migraines

    Alder could successfully compete with larger rivals Amgen, Lilly and Teva in preventing chronic migraines, analysts said Tuesday.

  • What’s Teva Pharmaceutical’s Research and Development Strategy?
    Market Realist3 days ago

    What’s Teva Pharmaceutical’s Research and Development Strategy?

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) laid out a detailed restructuring plan for the company to turn around its ailing business due to a number of challenges it’s facing.

  • Teva's Trisenox Gets FDA Approval as First-Line Treatment
    Zacks3 days ago

    Teva's Trisenox Gets FDA Approval as First-Line Treatment

    Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.

  • How Teva Pharmaceutical Plans to Improve Financial Profile
    Market Realist3 days ago

    How Teva Pharmaceutical Plans to Improve Financial Profile

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As we saw in the previous part of this series, Teva Pharmaceutical Industries (TEVA) is determined to pay down a considerable amount of its debt totaling $32 billion over the next few years. The company aims to achieve financial stability through improvement in operating profits and stable cash flow generation over the next few years.

  • How Teva Pharmaceutical Plans to Optimize Global Generics
    Market Realist3 days ago

    How Teva Pharmaceutical Plans to Optimize Global Generics

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate?

  • Globe Newswire3 days ago

    Antares Pharma Provides XYOSTED™ Regulatory Update

    Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company’s product, OTREXUP® (methotrexate) injection for subcutaneous use, is approved in the U.S. for the treatment of adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis.

  • How Teva Pharmaceutical Is Realigning Organizational Structure
    Market Realist4 days ago

    How Teva Pharmaceutical Is Realigning Organizational Structure

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? On December 14, 2017, Teva Pharmaceutical Industries (TEVA) announced its restructuring plan to cut costs by ~$3 billion over the next two years. It expects to witness a major turnaround of its business with the implementation of this plan.

  • What Are Insys Therapeutics’ Top Priorities?
    Market Realist4 days ago

    What Are Insys Therapeutics’ Top Priorities?

    Insys (INSY) is taking strategic steps to restore stakeholder confidence. The company aims to achieve one NDA (or new drug application) per year over the next five years. Insys is targeting treatments for orphan diseases, neurological diseases like pediatric epilepsy, genetic conditions like Prader-Willi syndrome, and treatments for secondary allergic reactions, anorexia, and products for opioid overdose.

  • Teva Pharmaceutical Focusing on Per Product Operating Profits
    Market Realist4 days ago

    Teva Pharmaceutical Focusing on Per Product Operating Profits

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has been focused on maximizing its revenues through its market-leading generics portfolio. The company, however, has been facing stiff competition in the generics market from Mylan (MYL), Gilead Sciences (GILD), and Pfizer (PFE), which has resulted in price erosion in the generics market.

  • Business Wire4 days ago

    Teva Announces U.S. FDA Approval of TRISENOX® (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic Leukemia

    Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration has approved the use of TRISENOX® injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia whose APL is characterized by the presence of the t translocation or PML/RAR-alpha gene expression.

  • Can Teva’s Debt Repayment Plan Deleverage Its Balance Sheet?
    Market Realist4 days ago

    Can Teva’s Debt Repayment Plan Deleverage Its Balance Sheet?

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has a debt of $34 billion on its balance sheet. The company is focused on reducing its net debt obligations to optimum levels over the coming years.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool6 days ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    These three small biotech stocks saw huge jumps. Can their momentum continue?

  • What’s behind Insys Therapeutics’ Legal Tangles?
    Market Realist6 days ago

    What’s behind Insys Therapeutics’ Legal Tangles?

    Thus, interaction with government agencies occurs regularly. Insys (INSY) has been a part of several government investigations recently. Insys received a subpoena in December 2013 from the inspector general of HHS for an investigation of potential violations that involved HHS programs.

  • Teva's Debt Cut to Junk by Moody's, Adding to Drugmaker's Woes
    Bloomberg6 days ago

    Teva's Debt Cut to Junk by Moody's, Adding to Drugmaker's Woes

    Teva Pharmaceutical Industries Ltd.’s credit rating was cut into junk territory by Moody’s Investors Service, adding to the company’s woes as revenue from its bestselling drug drops and it sells assets ...

  • A Look at Insys Therapeutics’ Financial Performance
    Market Realist6 days ago

    A Look at Insys Therapeutics’ Financial Performance

    Insys’s (INSY) net revenues decreased from $57.7 million in 3Q16 to $30.7 million in 3Q17, which was attributable to a decrease in Subsys sales. As a result, the gross profit of the company decreased to $23.1 million in 3Q17 as compared with $53 million for 3Q16. The general and administrative expenses of the company decreased to $15.7 million in 3Q17 as compared with $17.7 million for 3Q16.

  • MarketWatch6 days ago

    Teva credit rating downgraded to junk status at Moody's

    Teva Pharmaceuticals Industries Ltd.'s credit rating was downgraded two notches into junk status at Moody's Investors Service, which cited concerns over the drug maker's sizable debt. The rating agency ...

  • What Analysts Recommend for Insys Therapeutics and Peers
    Market Realist6 days ago

    What Analysts Recommend for Insys Therapeutics and Peers

    What to Expect from Insys Therapeutics in 2018Company overview

  • Teva to Lose 20–25 Sites, Cut 14,000 Workers in Next 2 Years
    Market Realist6 days ago

    Teva to Lose 20–25 Sites, Cut 14,000 Workers in Next 2 Years

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As part of its recent restructuring plan, Teva Pharmaceutical Industries (TEVA) announced a $3 billion restructuring plan in December 2017. As part of its cost-saving initiative, the company plans to shut down some of its manufacturing facilities and cut its employee base.

  • The Key Challenges Teva Pharmaceutical Is Facing
    Market Realist7 days ago

    The Key Challenges Teva Pharmaceutical Is Facing

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) announced a restructuring plan to recuperate sales. Its stock has had a bull run since the announcement, rising 44.5% since the company’s weak earnings results for fiscal 3Q17 on November 2, 2017.

  • Why Mizuho Securities Upgraded Teva Pharmaceutical to a ‘Buy’
    Market Realist7 days ago

    Why Mizuho Securities Upgraded Teva Pharmaceutical to a ‘Buy’

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate?Teva stock upgraded by Mizuho Securities

  • What Does Teva’s Recently Announced Restructuring Plan Entail?
    Market Realist8 days ago

    What Does Teva’s Recently Announced Restructuring Plan Entail?

    On December 14, 2017, Teva (TEVA) stock gained more than 10% on the back of the announcement of a comprehensive restructuring plan and additional measures to improve the company’s operational and financial performance. On December 14, 2017, the Generic Drugs ETF (GNRX) rose by approximately 1.0%. Teva Pharmaceuticals has a debt of $32 billion, which needs to be serviced in an organized manner to strengthen the company’s financials and bring down leverage.

  • Elagolix May Advance the Treatment Paradigm in Women’s Health
    Market Realist8 days ago

    Elagolix May Advance the Treatment Paradigm in Women’s Health

    On October 27, 2017, AbbVie (ABBV) announced that the New Drug Application (or NDA) for its investigational drug Elagolix, which is used for managing endometriosis-related pain, had been granted priority review by the FDA. AbbVie has developed Elagolix in collaboration with Neurocrine Biosciences (NBIX). AbbVie expects this oral gonadotropin-releasing hormone (or GnRH) antagonist to be approved by its Prescription Drug User Fee Act (or PDUFA) date in 2Q18.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes